Zenith Drugs Limited IPO: Issue Price, Listing Gain and Share Price Now
Zenith Drugs Limited listed on 27-Feb-2024 at ₹105.15 against an issue price of ₹79 , a listing gain of +33.10%. It last traded at ₹44. This page is the record of that issue and what has happened to it since — reported figures only.
Zenith Drugs Limited IPO: listing gain and return since
| Measure | Value |
|---|---|
| Issue price | ₹79 |
| Listing price (listing-day close) | ₹105.15 |
| Listing gain | +33.10% |
| Price now | ₹44 |
| Change from issue price | -44.30% |
| Change from listing-day close | -58.16% |
The two changes above answer different questions and are routinely opposite in sign. The change from the issue price is what an allottee has made. The change from the listing-day close is what somebody who bought on the first day has made.
Zenith Drugs Limited IPO details
| Issue term | Detail |
|---|---|
| Issue price (upper band) | ₹79 |
| Issue size | ₹40.68 Cr |
| Fresh issue | ₹33.94 Cr |
| Issue opened | 19-Feb-2024 |
| Issue closed | 22-Feb-2024 |
| Listed on | 27-Feb-2024 |
| Exchange | NSE SME |
| Segment | SME |
| Lead managers | Gretex Corporate |
How the Zenith Drugs Limited IPO was subscribed
| Category | Subscription |
|---|---|
| QIB | 106.72x |
| NII | 368.77x |
| Retail | 139.28x |
| Total | 179.18x |
Zenith Drugs Limited today
| Figure | Value |
|---|---|
| Market capitalisation | ₹75.4 Cr |
| Trailing P/E | 7.18x |
| Return on capital employed | 27.1% |
| Return on equity | 26.3% |
| 52-week high | ₹76 |
| 52-week low | ₹33.3 |
| Sector | Pharmaceuticals |
Fundamentals are as of the desk's last harvest and move with the market.
- Zenith Drugs Limited — full issue page: every stored figure, with its source.
- How many IPOs still trade above their issue price, corporate-action adjusted.
- The full IPO archive: listing gains by year, sector and issue size.
Automated data digest. This page is compiled automatically from exchange filings and public aggregator data. It is a record of reported figures — it is not research, not a recommendation, and not investment advice.
Grey Market Premium (GMP) is an unofficial, unregulated price quoted outside the exchanges. It is not a forecast of the listing price and is frequently wrong.
Published by INVESTOLOGY — SEBI Registered Research Analyst INH000015297. Investments in securities markets are subject to market risk; read all offer documents carefully before investing. Registration granted by SEBI and NISM certification in no way guarantee performance or assure returns.